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Healthcare reforms in Brazil began in 1988 as part of 
a broader sociopolitical movement at the end of nearly 
20 years of military rule. The new constitution was 
underpinned by principles of budgetary and political 
decentralisation, community participation in local 
budget setting, and the acknowledgment that health 
and access to healthcare is a universal human right. This 
laid the foundation for the Sistema Único de Saúde, or 
Unified Health System, and began a nationwide shift 
from tertiary centre based healthcare to comprehensive 
primary healthcare, free at the point of use, funded by 
the taxpayer, and inspired by the Alma-Ata Declaration 
of 1978.
Over the past 15 years progress in Brazilian pub-
lic health has been remarkable. Infant mortality has 
dropped from 48 per 1000 to 17 per 1000. In just the 
past five years, hospital admissions due to diabetes or 
stroke have decreased by 25%, the proportion of chil-
dren under 5 years old who are underweight has fallen 
by 67%, over 75% of women now receive seven or more 
antenatal consultations, and diphtheria, tetanus, and 
pertussis (DTP) vaccine coverage in children less than 
1 year old is greater than 95% in most municipalities.1 
Even the United Nations Millennium Development Goals 
aspire to achieve less than this.2
Although these measures reflect improvements in 
the entire health system, evidence suggests that the 
lynchpin for the successes of the Unified Health S ystem 
is the P rograma Saúde da Família, or Family Health 
Programme, implemented a few years after the con-
stitutional reforms.3 4 This programme has expanded 
nationally and now provides comprehensive primary 
care services in 95% of all municipalities, covering over 
55% of the population—more than 85 million people. 
The Family Health Programme is based on a simple 
model—multidisciplinary teams, comprising a doctor, 
nurse, nurse auxiliary, and four to six community health 
workers, work in health units located in geographically 
defined areas, each covering no more than 5000 resi-
dents. A community health worker is responsible for up 
to 120 families in a defined area, and aims to provide 
home visits to every household at least once a month. 
Community health workers are fully integrated into 
the primary care team. They are multifunctional, and 
although child and maternal health forms the bulk of 
their work, they also provide curative care, triage and 
referral into the health unit, health promotion for chronic 
disease, and support and encouragement for community 
participation: community health workers must be from 
and live in the area where they work.
Budgetary and logistic responsibility for the health 
units has been devolved to the municipality level, which 
permits flexibility and autonomy in the delivery of this 
model of primary healthcare. However, healthcare 
expenditure is federally mandated, with contributions 
from the regional and national coffers. The scale of this 
healthcare reform is unprecedented, and it is expanding 
to reach universal coverage. In just 15 years, Brazil has 
recruited an army of 250 000 community health workers 
and 30 000 medical generalists.
Despite these remarkable achievements, the Family 
Health Programme is confronting challenges that can pro-
vide useful lessons for other countries. These challenges 
include difficulties in the recruitment and retention of doc-
tors trained appropriately to deliver primary healthcare, 
large variations in the quality of local care, patchy integra-
tion of primary care services with existing secondary and 
tertiary care,5 and the slow adoption of the Family Health 
Programme in large urban centres,6 where the middle 
classes are more accustomed to private healthcare. Further-
more, although the Family Health Programme costs only 
$31-50 (£20-32; €24-39) per capita per year,7 the mainte-
nance of adequate financing to support the expansion of 
primary care nationally has sometimes been problematic.8
Brazil’s Family Health Programme is probably the most 
impressive example worldwide of a rapidly scaled up, cost 
effective, comprehensive primary care system. But its suc-
cesses have not been given the international recognition 
they deserve. The potential of the healthcare reforms in 
Brazil and, specifically, of the Family Health Programme, 
to deliver affordable healthcare was noted 15 or more 
years ago in the BMJ.9 10 In many ways that promise has 
been more than fulfilled, but Brazil’s primary healthcare 
success story remains poorly understood and not yet 
widely disseminated, or translated into other contexts. 
High income countries could also learn from how the 
programme has affected chronic disease, demand for ter-
tiary care services, and health promotion. Through the 
Family Health Programme, community health workers 
proactively identify problems in chronic disease manage-
ment and medication adherence; they support healthy 
lifestyle choices through home based health promo-
tion and education; they provide continuously updated 
population registers and ensure disease surveillance is 
population based, not just based on those who interface 
with formal healthcare services; and, finally, they can also 
proactively identify simple acute health problems that can 
be dealt with in the home. These are all tasks that the 
UK NHS still struggles with. The lessons from Brazil may 
be particularly relevant in the current economic climate.
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In many respects, Brazil has got it right: a cost effec-
tive, large scale primary healthcare programme that 
addresses the public health problems typical of low 
income countries and those undergoing the epidemio-
logical transition, but one that is also relevant to high 
income countries. Brazil’s growing global political and 
economic ascendency11 should encompass its leadership 
role in primary healthcare. We all have a lot to learn—get 
the system right, and the results will follow, even with 
limited resources.
Health policy makers in the UK have a history of look-
ing to the United States for innovative examples of health-
care delivery, despite the relatively poor outcomes and 































Referral from primary to secondary care
Older and more deprived patients remain at a disadvantage
Only a minority of people require hospital services, 
most people treat themselves or consult a generalist.1 
General practitioners, who are usually the first point 
of contact for patients, must decide which patients to 
refer to s econdary care.2 We do not know the extent to 
which people who are denied access to specialist serv-
ices by the gatekeeper are disadvantaged. Some may be 
denied timely access to experts who are best placed to 
help. Alternatively, others may be harmed by unneces-
sary diagnostic tests and interventions. Therefore, the 
appropriate referral of cases to secondary care has 
e conomic, quality, and safety ramifications that reso-
nate across the health sector and the globe. In light of 
this, the linked study by McBride and colleagues, 
p resenting referral data for 130 000 British patients, is 
useful.3
A conceptual framework that could be used to analyse 
this study was published by Glasziou and Haynes.4 It pro-
poses that, for patients to receive evidence based care, 
their doctor must be aware of the latest research findings, 
accept the need to act on that evidence, and target the 
patients who might benefit from that research. Interven-
tions should be practical and recalled by the practitioner 
at the time of the consultation.4 Finally, the patient and 
the practitioner should agree on the necessary action, 
and the task must be completed. In practice, if each step 
were completed 80% of the time, then the appropriate 
management would occur in only one in five encounters 
with relevant patients.
According to McBride and colleagues a respectable 
but still unsatisfactory 61.4% of women with postmeno-
pausal bleeding were referred despite ample evidence of 
benefit from referral.3 Furthermore, the three conditions 
examined in the study—hip pain, postmenopausal bleed-
ing, and gastric cancer—are more common in older people 
and in deprived communities. However, older patients (85 
years or older) with postmenopausal bleeding or hip pain 
were significantly less likely to be referred than younger 
patients (55-64 year olds). Patients who were more 
deprived and had hip pain and dyspepsia (if under 55 
years old) were also less likely to be referred.
The authors suggest several explanations. Setting aside 
the possibility that younger people and more affluent peo-
ple may be over-referred, the reasons for under-referral 
include the possibility that specialist services are not as 
readily available in socially disadvantaged areas. The 
high prevalence of chronic and complex conditions in 
deprived communities or unrecognised factors related to 
general practitioners may result in atypical referral pat-
terns. Perhaps the need for referral is not recognised or 
referral is not possible in some circumstances.
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In primary care the decision to refer or offer further 
treatment is made during a brief medical consultation, 
in which the patient will usually present undifferentiated 
symptoms, sometimes among a host of unrelated prob-
lems.5 The extent to which the patient’s problem is appro-
priately dealt with is a function of how effectively the 
doctor and patient communicate. Sometimes treatment 
decisions follow a series of consultations after several 
objective tests. All of these factors—including consulta-
tion skills, continuity of care, and the correct interpreta-
tion of test results—introduce risk and may reduce the 
chances that the patient is referred.
The reasons for seeking an expert opinion have 
remained unchanged for decades and are not limited 
to diagnosis or treatment. In many cases patients are 
referred for reassurance as a response to perceived 
medico legal risk, to avert a complaint, or to share the bur-
den of caring for a patient whose problems are resistant 
to appropriate treatment.6 It is unsafe to assume that the 
reasons for referral can be readily gleaned in any docu-
ment or database. Neither do doctors always record the 
multiple reasons for referral in their records.7
Research using databases is attractive because it can 
use data from thousands of cases to explore several inter-
esting associations. However, databases cannot provide 
information to help understand patterns that arise from 
human interactions. McBride and colleagues suggest that 
patient preferences may explain some of the discordant 
patterns of referral.3 Older people may be less willing to 
be referred for investigation, may be reticent because of 
social isolation, or may adopt a stoic attitude to symptoms. 
Whatever the reasons they are almost certainly best under-
stood within the context in which they were observed.
Research is needed on the interaction between doctors 
and patients in the primary care consultation, which ulti-
mately determines who is referred and who is not. Caution 
is needed in generalising the results to other primary care 
systems because the results will be context specific, even 
within national boundaries. 
1	 Green	LA,	Fryer	GE	Jr,	Yawn	BP,	Lanier	D,	Dovey	SM.	The	ecology	of	

















Improving access to treatment for HIV in  
sub-Saharan Africa
Additional funding is important, but using it more efficiently is key 
Between 2000 and 2007, funding for HIV and AIDS pro-
grammes increased from $2.4bn (£1.5bn; €1.8bn) to 
$10bn. Antiretroviral drugs are the costliest component 
of delivering antiretroviral treatment, making up at least 
half of total treatment costs (excluding programme level 
costs) in low, lower middle, and upper middle income 
countries, respectively.1
Previous analyses have noted that in developing coun-
tries as coverage of antiretroviral treatment increases the 
cost falls. Others have focused on factors that influence 
the cost of antiretrovirals: third party negotiations, vol-
ume commitment, the country’s income, costs of active 
drug ingredients, and product type—generic or innova-
tive.2  3
In the linked study(doi: 10.1136/bmj.c6218), Ben-
david and colleagues looked at the dramatic fall in the 
cost of first line antiretroviral drugs that accompanied the 
equally dramatic rise in foreign assistance between 2003 
and 2008 in 13 countries in sub-Saharan Africa.4 Unsur-
prisingly, they found that both factors were significantly 
associated with increasing coverage. They also found that 
the country’s own public health expenditure and a com-
posite World Bank measure of government effectiveness 
were also positively associated with increases in coverage.
Undoubtedly, increases in funding and dramatic price 
reductions have been crucial determinants of the rapid 
scaling up of antiretroviral treatment over the past seven 
years. However, two caveats should be considered when 
interpreting the results of the study. Firstly, the authors 
do not to use the word “causal” when describing the 
association between increases in coverage, changes in 
antiretroviral prices, and official development assistance; 
however, most of their discussion focuses on the degree 
to which the observed factors seem to have determined 
coverage and are likely to determine it in the future, thus 
implicitly suggesting causality. The authors do not con-
sider, for example, that the increased worldwide demand 
for antiretroviral drugs might have contributed to the 
cost reductions. Just as falling drug prices might enable 
increases in coverage, increased demand for antiretroviral 
drugs might result in a drop in price.
Secondly, fig 1 in Bendavid and colleagues’ study 
shows that the antiretroviral market has changed dramat-
ically over time. In 2003, countries varied greatly in the 
price of first line treatment, with little variability in cov-
erage. By 2008, the opposite was true. The analysis used 
to estimate the price-coverage association assumes that 
the structure of the market is constant over time, which 
could bias the estimated association between coverage 
and prices. The study may therefore have overestimated 
the importance of the cost of antiretrovirals in determin-
ing the coverage of antiretroviral treatment from 2003 to 
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2008. More importantly, it may also have underestimated 
the effects of further reductions in the total cost of provid-
ing treatment (including reduced cost of antiretrovirals) 
on global efforts to expand treatment for HIV in these dif-
ficult economic times.
During the initial period of rapid expansion of antiret-
roviral treatment (2003-8), health systems lacked suffi-
cient capacity to deliver treatment. Supply chains were 
weak, health workers were not trained, and laborato-
ries were working at low capacity. Thus, as well as the 
affordability of drugs, logistic constraints restricted the 
expansion of treatment. Even when clinics were staffed 
and supplied with antiretrovirals, patient demand was 
often low because few people were aware of their HIV 
status. Over the past decade, large investments have 
been made in developing the infrastructure needed to 
test for HIV and treat it; this has occurred concurrently 
with increases in funding and a drop in antiretroviral 
prices.
Reducing the price of current lowest cost first line regi-
mens will probably not increase coverage greatly, but 
such efforts are still warranted. Widespread dissatisfac-
tion with the complexity and toxicity of the lowest cost 
regimen is prompting multiple efforts to improve it, as 
reflected in the UNAIDS/WHO “Treatment 2.0” initia-
tive. These efforts include optimising the dose of current 
drugs to reduce cost and toxicity; reducing the production 
costs of better but more expensive first line drugs, such 
as tenofovir; and introducing new higher potency, lower 
cost first line drugs. In the future, an increasing propor-
tion of patients will need second line drugs as the first 
generations of patients who had access to antiretroviral 
treatment develop treatment failure. This will put severe 
cost pressure on antiretroviral treatment programmes, 
limiting their ability to enrol new patients in first line 
treatment or move patients on to second line treatment (or 
both). Strategies to lower the cost of second line antiret-
roviral treatment and to maximise the durability of first 
line treatment will be essential.
If 2003-8 was a time of rapidly increasing development 
aid for antiretroviral treatment and constrained supply 
and demand for services, 2010-5 is likely to be a time of 
austerity. If coverage over the next decade is more con-
strained by resources than by capacity, then reducing 
the total cost of providing treatment, including the drug 
component, may have an even greater effect on future 
coverage than did reductions in drug costs between 2003 
and 2008. As Bendavid and colleagues argue, continued 
increases in the coverage of antiretroviral treatment will 
depend crucially on mobilising additional domestic and 
international resources. However, improving the effi-

















Implantable cardioverter defibrillators after acute 
myocardial infarction
Evidence suggests no overall survival benefit if inserted within 40 days
Despite major advances during the past two decades in the 
management of patients with acute myocardial infarction, 
sudden cardiac death remains an important contributor 
to overall mortality.1 Several randomised controlled tri-
als have established the effectiveness of implantable 
cardioverter defibrillators in reducing overall mortality 
in patients with a history of myocardial infarction and 
reduced left ventricular ejection fraction.2 Although the 
risk of sudden cardiac death is greatest in the first 30 days 
after acute myocardial infarction, especially in patients 
with left ventricular dysfunction or heart failure,3 two 
trials found that the insertion of an implantable cardio-
verter defibrillator at this early stage did not reduce all 
cause mortality.4  5 A possible reason is an increase in non-
arrhythmic death in the early post-infarct period. The find-
ings of many of the early trials of implantable cardioverter 
defibrillators are reflected in current national and interna-
tional guidelines, which recommend that these devices 
should be considered in patients with a previous myocar-
dial infarction (after at least 40 days) and left ventricular 
ejection fraction below 30-35%.6  7
A recent study has shed further light on why early 
insertion of an implantable cardioverter defibrilla-
tor soon after acute myocardial infarction may not 
improve survival.8 The investigators examined the avail-
able autopsy records of patients who had died in the 
VALsartan In Acute myocardial infarctioN Trial 
(VALIANT), which randomised 14 703 patients with clini-
cal evidence of heart failure or left ventricular dysfunction 
after an acute myocardial infarction to valsartan, capto-
pril, or both.9 In the 95 patients with presumed sudden 
cardiac death, the contribution of recurrent myocardial 
infarction or cardiac rupture to death was highest in the 
first month after the index infarction and decreased with 
time. In contrast, the proportion of deaths attributable to 
arrhythmia (presumed in the absence of specific acute 
autopsy findings other than those of the index infarction) 
was higher than that for recurrent myocardial infarction 
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or cardiac rupture after three months and increased sig-
nificantly over time. Despite the usual limitations of stud-
ies involving retrospective analyses of autopsy findings, 
such as autopsies being performed only in a subset of 
patients (autopsy reports were available for 398 (13.8%) 
of the 2878 patients who died in the VALIANT study) and 
the potential variability in the quality of autopsies, this 
study provides important insights into the mode of sud-
den cardiac death in survivors of acute myocardial infarc-
tion. The findings lend further support to the notion that 
non-arrhythmic death may be a more important cause of 
death in the early stages after acute myocardial infarc-
tion, which would explain the overall lack of benefit on 
mortality when implantable cardioverter defibrillators 
are inserted within one month of the index event. This 
study strengthens the current recommendations that these 
devices should not be inserted within 40 days of an acute 
myocardial infarction.
However, several questions remain unresolved. 
Although the study found that in the first month sudden 
cardiac death had mainly non-arrhythmic causes (24/30 
cases), a fifth of such deaths (6/30) had an arrhythmic 
cause, which might have been prevented by the early 
insertion of an implantable cardioverter defibrillator. A 
subset of patients at high risk of sudden arrhythmic death 
early after acute myocardial infarction would therefore 
not be considered for potentially life saving treatment if a 
blanket policy of not inserting these devices until at least 
40 days after infarction is strictly adhered to.
The reasons why a patient may develop ventricular 
arrhythmias and die suddenly are complex.10 This is 
reflected by the range of invasive and non-invasive tests 
that can help predict the risk of sudden cardiac death. 
A more pertinent question is how we can best identify 
which patients who have had an acute myocardial infarc-
tion are at greatest risk of developing life threatening ven-
tricular arrhythmias and would benefit most from early 
insertion of a cardioverter defibrillator.
The answer may lie in the use of a combination of tests 
or algorithms designed to define the arrhythmogenic 
substrate in people who survive acute myocardial infarc-
tion, thereby providing a more tailored approach. This 
approach also allows implantable cardioverter defibril-
lators to be considered in patients with left ventricular 
ejection fraction above 30-35% who do not warrant such 
a device under current guidelines but may still be at risk 
for sudden cardiac death.11 Until such algorithms have 
been designed and validated in large multicentre stud-
ies, clinicians will continue to practise evidence based 
medicine, which is reflected in current national and inter-
national guidelines on the selection of candidates for the 
insertion of implantable cardioverter defibrillators after 
acute myocardial infarction.
When is the optimal time to insert an implantable car-
dioverter defibrillator? The answer is still unresolved, 
although current evidence suggests no overall survival 
benefit for devices inserted within 40 days of infarction. 
From a health economic perspective, implantable cardio-
verter defibrillators become more cost effective the longer 
the patient survives after implantation.12 It could there-
fore be argued that these devices should be considered 
only after patients have overcome the risks and compli-
cations of the initial acute myocardial infarction (such 
as recurrent infarction and cardiac rupture) and if their 
left ventricular ejection fraction remains below 30-35%, 
despite being on optimal medication to improve left ven-
tricular function. Clearly, more work is needed in this area 
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Although the coalition government’s plans to put general 
practices in charge of commissioning have attracted wide-
spread interest and comment, its proposals for provider 
reform are equally radical. By 2013 it is expected that all 
NHS trusts will have become foundation trusts, and that 
providers from the independent sector will play a bigger 
part in delivering services to NHS patients. The govern-
ment also wants to encourage employee owned healthcare 
providers, with the aim of creating “the largest and most 
vibrant social enterprise sector in the world.”1
These plans are part of a broader programme of public 
service reform, at the heart of which is a concern to move 
away from state ownership to greater diversity in how pub-
lic services are run in pursuit of the “big society.”2 Cabinet 
office minister Francis Maude announced recently that the 
government will take this programme forward by putting 
in place a right for public sector workers to take over the 
running of their services.3 This builds on the previous gov-
ernment’s interest in mutualism in the public sector, and 
it signals a renewed commitment to explore alternatives to 
state ownership and for profit private provision.4
Cross party support for public service mutuals derives in 
part from concern that state run services can be slow mov-
ing and unresponsive to the needs of users, and in part from 
evidence that employee ownership brings benefits in terms 
of increased productivity, reduced staff absenteeism and 
turnover, and higher levels of innovation. Experience has 
shown, however, that employee ownership in itself is not 
sufficient to deliver the advantages claimed for mutuality.5 
Equally important is staff involvement in decision making 
and the development of a culture of ownership that gives 
staff a real voice in the organisation.
Central Surrey Health is the longest standing example of 
an employee owned organisation created by staff previously 
employed directly by the NHS. Established in 2006 as a not 
for profit limited liability company owned by its employees, 
Central Surrey Health employs around 770 nurses, thera-
pists, and support staff, who deliver care to NHS patients 
in the community under a contract with the primary care 
trust. As co-owners of the company, workers are involved 
in shaping the organisation’s future as well as delivering 
patient services.
The pioneering work of Central Surrey Health is being 
taken forward in 61 other initiatives in the NHS in England 
under the “right to request” introduced in 2008, which 
has enabled staff providing community services to set up 
social enterprises. These initiatives vary in their scope and 
focus, ranging from small scale projects aimed at meeting 
the needs of specific groups of patients to schemes where all 
the community services previously managed by a primary 
care trust are taken into employee ownership. The Depart-
ment of Health has estimated that services to the value of 
£900m (€1060m; $1450m) that employ almost 25 000 staff 
will be affected.6
The future of employee ownership outside community 
services hinges on how the government takes forward its 
commitment to allow foundation trusts to go down this 
route. The white paper on NHS reform published in July 
stated that, “As all NHS trusts become foundation trusts, 
staff will have the opportunity to transform their organi-
sations into employee-led social enterprises that they 
themselves control, freeing them to use their front-line 
experience to structure services around what works best 
for patients.”1 The implication is that, in future, founda-
tion trusts will take different forms, with some retaining the 
current governance model involving multiple stakeholders, 
while others become employee owned.
Several practical barriers may get in the way of the gov-
ernment realising its ambition. These barriers include 
maintaining access to NHS pensions for staff making the 
transition, and ensuring that employee owned organisa-
tions are not at a disadvantage in the application of tax 
rules. Also important is providing access to legal, financial, 
and other advice to organisations considering going down 
this route, as well as support from employee owned compa-
nies in other sectors able to offer mentoring and guidance.
In promoting mutuals, the government will also have to 
tackle concerns that employee ownership entails the pri-
vatisation of NHS services. The support given by the former 
Labour government to public service mutuals suggests 
that these concerns may not be insurmountable, even if 
trades unions need to be persuaded that their members will 
benefit. The history of workers’ cooperatives in the labour 
movement may also make it easier to promote diversity in 
service provision through employee ownership than by giv-
ing investor owned companies a bigger role in healthcare.
Assuming that public service mutuals are here to stay, 
they need to be given time to evolve if they are to emulate 
the levels of customer service, quality, and innovation seen 
in organisations like the John Lewis Partnership. Giving 
staff a stake in the organisations they work for needs to be 
combined with much deeper staff engagement in decision 
making than has traditionally been the case in the NHS 
and real empowerment of front line teams. Changing cul-
tures is much more difficult than altering structures, but it 
is essential if further improvements in performance are to 
be achieved. This has implications for workplace relation-
ships and calls for leadership styles that foster collabora-
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